Skip to content

Medical treatment with nitroglycerin for management of retained placenta - a multicentre trial - Nitroglycerin for management of retained placenta - a multicenter trial

Medical treatment with nitroglycerin for management of retained placenta - a multicentre trial - Nitroglycerin for management of retained placenta - a multicenter trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2008-001346-92-SE
Enrollment
Unknown
Registered
2008-04-07
Start date
2008-05-23
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Background: retained placenta occurs in 3% of all deliveries. The results from a pilot study indicate that medical treatment with a combination of oxytocin and the utero-relaxing agent nitroglycerin adminstered 1mg sublingually seems to have effect. The primary aim of this study is to investigate in a larger multicentre trial if the good results from the pilot study using nitroglycerin for management of retained placenta can be confirmed.

Interventions

Trade Name: Nitromex 0,5mg resoritablet Product Name: Nitromex resoritablet 0,5mg Product Code: GTN Pharmaceutical Form: Sublingual tablet CAS Number: 55630 Other descriptive name: GLYCERYL TRINITRATE

Sponsors

No sponsor
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Healthy woman with no medication 2. Uncomplicated vaginal delivery 3. Term pregnancy (>37 weeks) 4. Retained placenta 45 minutes after delivery 5. The woman wishes to participate in the study 6. No excessive vaginal bleeding (=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1. Excessive vaginal bleeding 2. Preterm labour 3. Daily medication 4. Placenta accreta/percreta 5. Known uterine abnormailty

Design outcomes

Primary

MeasureTime frame
Main Objective: Main objective: To study the effect of medical treatment with 1mg of nitroglycerin administered sublingually on retained placenta, i.e.does placenta detach on the treatment.;Secondary Objective: Secondary objectives: To measure blood loss on the treatment compared to placebo group, to study possible side effects such as headache, palpitations, hot flushes, and to study possible effects on blood preassure and pulse rate.;Primary end point(s): Primary end point is to evaluate in a multicenter double-blind randomised study evaluate if sequental medical treatment with oxytocin 10 IU intravenously and 1mg of Nitromex sublingually is effective in detaching retained placenta compared to oxytocin 10 IU and placebo.

Countries

Sweden

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026